MTOR and autosomal dominant polycystic kidney disease: ADPKD, autosomal dominant polycystic kidney disease; Aza, azathioprine; CsA, cyclosporin A; DM, diabetes mellitus; GN, glomerulonephritis; HD, hemodialysis; HTN, hypertension; ICGN, immune-complex glomerulonephritis; IS, immunosuppressants; KS, Kaposi sarcoma; LN, lupus nephritis; MMF, mycophenolate mofetil; MN, membranous nephropathy; MPGN, membranoproliferative glomerulonephritis; mTOR, mammalian target of rapamycin; Pred, prednisolone; Tac, tacrolimus